Category Archives: Regional News

You are here: Home » Category: "Regional News"

BioCryst Presents Data Highlighting the Rapid and Sustained Plasma Concentrations of BCX7353 in HAE Patients at the Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology

RESEARCH TRIANGLE PARK, N.C., Nov. 16, 2018 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today presented data showing that an oral formulation of BCX7353 was rapidly absorbed and exhibited a long half-life, two important characteristics of desired new acute treatments for hereditary angioedema (HAE) attacks, at the Annual Scientific Meeting of the American College of Allergy, Asthma &…

[Read More]

Fennec Pharmaceuticals Announces Scientific Symposium on Ototoxicity in Pediatric Cancer Patients at the 50th Congress of the International Society of Pediatric Oncology (SIOP) 2018 Meeting  

RESEARCH TRIANGLE PARK, N.C., Nov. 16, 2018 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today presented data showing that an oral formulation of BCX7353 was rapidly absorbed and exhibited a long half-life, two important characteristics of desired new acute treatments for hereditary angioedema (HAE) attacks, at the Annual Scientific Meeting of the American College of Allergy, Asthma &…

[Read More]

What Happens When Hyperhidrosis Goes to Carnegie Hall?

RESEARCH TRIANGLE PARK, N.C., Nov. 16, 2018 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today presented data showing that an oral formulation of BCX7353 was rapidly absorbed and exhibited a long half-life, two important characteristics of desired new acute treatments for hereditary angioedema (HAE) attacks, at the Annual Scientific Meeting of the American College of Allergy, Asthma &…

[Read More]

Diffusion Pharmaceuticals Chief Scientific Officer Dr. John L. Gainer to Present at 2018 Annual Meeting of the Society for NeuroOncology

RESEARCH TRIANGLE PARK, N.C., Nov. 16, 2018 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today presented data showing that an oral formulation of BCX7353 was rapidly absorbed and exhibited a long half-life, two important characteristics of desired new acute treatments for hereditary angioedema (HAE) attacks, at the Annual Scientific Meeting of the American College of Allergy, Asthma &…

[Read More]

Hemispherx Reports 2018 Third Quarter and First Nine Months Financial Results

RESEARCH TRIANGLE PARK, N.C., Nov. 16, 2018 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today presented data showing that an oral formulation of BCX7353 was rapidly absorbed and exhibited a long half-life, two important characteristics of desired new acute treatments for hereditary angioedema (HAE) attacks, at the Annual Scientific Meeting of the American College of Allergy, Asthma &…

[Read More]

Cabaletta Bio Expands Scientific Regulatory, and Cell Therapy Manufacturing Expertise with Scientific Advisory Board Additions

RESEARCH TRIANGLE PARK, N.C., Nov. 16, 2018 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today presented data showing that an oral formulation of BCX7353 was rapidly absorbed and exhibited a long half-life, two important characteristics of desired new acute treatments for hereditary angioedema (HAE) attacks, at the Annual Scientific Meeting of the American College of Allergy, Asthma &…

[Read More]

Helius Medical Technologies, Inc. Announces Pricing of Public Offering of Class A Common Stock

RESEARCH TRIANGLE PARK, N.C., Nov. 16, 2018 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today presented data showing that an oral formulation of BCX7353 was rapidly absorbed and exhibited a long half-life, two important characteristics of desired new acute treatments for hereditary angioedema (HAE) attacks, at the Annual Scientific Meeting of the American College of Allergy, Asthma &…

[Read More]

Neuronetics to Present at the 30th Annual Piper Jaffray Healthcare Conference

RESEARCH TRIANGLE PARK, N.C., Nov. 16, 2018 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today presented data showing that an oral formulation of BCX7353 was rapidly absorbed and exhibited a long half-life, two important characteristics of desired new acute treatments for hereditary angioedema (HAE) attacks, at the Annual Scientific Meeting of the American College of Allergy, Asthma &…

[Read More]

Inovio Prepares for Growth & Commercialization With Leadership Appointments

RESEARCH TRIANGLE PARK, N.C., Nov. 16, 2018 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today presented data showing that an oral formulation of BCX7353 was rapidly absorbed and exhibited a long half-life, two important characteristics of desired new acute treatments for hereditary angioedema (HAE) attacks, at the Annual Scientific Meeting of the American College of Allergy, Asthma &…

[Read More]

The World's First Combined Endoscopic and Robotic-Guided Spine Surgery is Performed by Surgeons at Virginia Spine Institute

RESEARCH TRIANGLE PARK, N.C., Nov. 16, 2018 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today presented data showing that an oral formulation of BCX7353 was rapidly absorbed and exhibited a long half-life, two important characteristics of desired new acute treatments for hereditary angioedema (HAE) attacks, at the Annual Scientific Meeting of the American College of Allergy, Asthma &…

[Read More]